<DOC>
	<DOCNO>NCT00344682</DOCNO>
	<brief_summary>This study evaluate efficacy safety drug memantine ( trade name NAMENDA ) augmentation agent treatment depression people fully respond antidepressant medication .</brief_summary>
	<brief_title>Memantine Augmentation Antidepressants</brief_title>
	<detailed_description>- Objective The objective study evaluate efficacy safety 20 mg memantine administer daily augmentation agent subject take antidepressant least 1 month experience incomplete absent therapeutic response . - Background Memantine moderate affinity , uncompetitive N-methyl-D-aspartate ( NMDA ) receptor antagonist approve treatment moderate-to-severe dementia Alzheimer 's type . It commercially available 23 country worldwide since 1982 . There report publish literature suggest NMDA receptor may involve etiology depressive disorder . The NMDA antagonist ketamine show antidepressant effect placebo-controlled clinical trial ( Berman et al. , 2000 ) . Uncompetitive NMDA receptor antagonist , include memantine , show exhibit antidepressant-like activity animal model depression ( Moryl et al. , 1993 , Papp Moryl 1994 ) . Animal study also support possibility uncompetitive NMDA receptor antagonist may work synergistically combination antidepressant animal model depression ( Rogoz et al. , 2001 ) . Some author hypothesize role NMDA receptor therapeutic effect numerous antidepressant ( Skolnick et al. , 1996 ) . - Study Design Duration This randomize , single site , double-blind , placebo-controlled , parallel-group study outpatient . The study consist 8-week double-blind treatment period . Approximately 25 patient randomized treatment group ( memantine placebo ) total approximately 50 patient .</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>Male female patient 18 85 year age screening . Patients must provide write informed consent prior study entry . Patients must meet DSMIVTR ( Diagnostic Statistical Manual IV Text Revision ) criteria Major Depressive Episode severity mild , moderate severe partial remission , confirm MINI . Patients must HAMD ( 17item ) score 16 high . Patients must 1 follow medication 4 week list dose psychiatric medication dose change past 25 day : 20 mg qD fluoxetine ( Once Daily ) 50 mg qD sertraline 20 mg qD paroxetine 200 mg qD fluvoxamine 20 mg qD citalopram 10 mg qD escitalopram 150 mg qD venlafaxine venlafaxine sustain release 300 mg qD bupropion bupropion sustain extend release 15 mg qD mirtazapine 60 mg qD duloxetine Participants must agree keep dose exist antidepressant ( ) constant throughout 8week trial . Diagnosis bipolar disorder schizophrenic schizoaffective disorder . History alcohol drug abuse dependence within 6 month enrollment . Patients receive ECT ( Electroconvulsive Therapy ) past 3 month . History seizure . Moderate dementia ( MMSE score 20 less ) . Active suicidal ideation : endorse 3 ( severe score ) QIDSSR ( Quick Inventory Depression Symptomatology Self Reports ) suicide item OR score 2 high past week Suicide Scale item 4 5 ( current suicidal ideation moderate strong would avoid take step save life ) . Currently take mood stabilizer antipsychotic ( except lithium clearly use augment agent ) . Patients , opinion investigator , might suitable study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>memantine</keyword>
	<keyword>Namenda</keyword>
	<keyword>augmentation</keyword>
	<keyword>add-on</keyword>
	<keyword>depression</keyword>
	<keyword>MDD ( major depressive disorder )</keyword>
	<keyword>unipolar depression</keyword>
	<keyword>NMDA</keyword>
	<keyword>ketamine</keyword>
	<keyword>uncompetitive NMDA receptor antagonist</keyword>
</DOC>